Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Trial Profile

Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Methotrexate; Methotrexate; Methylprednisolone; Prednisone; Vincristine
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms Inter-B-NHL ritux 2010
  • Most Recent Events

    • 14 Sep 2016 This trial was suspended in Poland, according to European Clinical Trials Database.
    • 11 Jun 2016 The study is suspended in Spain and Poland and is completed in Italy.
    • 07 Jun 2016 Interim results (n=310) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top